Core Insights - HeartFlow, an AI-powered cardiac diagnostics firm, recently reported an insider buy by Board member Jeffrey Lightcap, who acquired 40,000 shares valued at approximately $1.1 million on December 16, 2025 [1][2][9] Company Overview - HeartFlow specializes in AI-driven, non-invasive diagnostic solutions for coronary artery disease, utilizing the HeartFlow Platform for 3D heart modeling and blood flow analysis [7][8] - The company operates a platform-based business model, providing software and analytics services to healthcare providers, including hospitals and cardiology clinics [7] - As of December 16, 2025, HeartFlow's market capitalization stands at $2.5 billion, with a revenue of $161.88 million and a net income loss of $125.37 million over the trailing twelve months [4] Transaction Details - Jeffrey Lightcap's recent purchase establishes a direct holding of 40,000 shares, which represents approximately 0.59% of his total HeartFlow holdings, including substantial indirect exposure of 6,697,556 shares [6] - The transaction is a straightforward open-market purchase with no derivative or option components involved [6] Financial Performance - HeartFlow's revenue is experiencing rapid growth, with a 41% year-over-year increase in the third quarter, reaching $46.3 million [10] - The company forecasts a 38% year-over-year revenue increase for the full year 2025, projecting around $173 million [10] - Despite strong revenue growth, HeartFlow reported a significant net loss of $50.9 million in Q3, compared to a loss of $19.1 million in the previous year, raising concerns about its financial health [11] Market Sentiment - Lightcap's purchase suggests a bullish outlook on HeartFlow, particularly as it occurred after the stock hit a 52-week low of $25.38 [9]

Core Insights - Schusterman Interests has initiated a new position in HeartFlow, Inc. by acquiring over 1.9 million shares valued at $65.3 million, making it the fund's fourth-largest holding [2][3][10] Company Overview - HeartFlow, Inc. specializes in advanced, non-invasive diagnostic tools for coronary artery disease, leveraging artificial intelligence and computational modeling to improve clinical decision-making and patient outcomes [6] - The company generates revenue primarily from its proprietary AI-powered HeartFlow Platform and related healthcare information services [6] Financial Metrics - As of the latest market close, HeartFlow shares are priced at $32.25, reflecting a 70% increase from the IPO price of $19 [4][11] - HeartFlow's market capitalization stands at $2.7 billion, with a total revenue of $161.9 million and a net income of -$125.4 million for the trailing twelve months [5] Investment Context - The acquisition by Schusterman Interests represents 14.9% of the fund's 13F reportable assets under management, indicating a significant allocation to HeartFlow [7][10] - The investment reflects confidence in HeartFlow's technology and its potential for durable revenue growth in a large, under-digitized market [9][11]

Core Insights - Bain Capital Life Sciences Investors, LLC has acquired a significant stake in HeartFlow, Inc., purchasing 12,448,158 shares valued at approximately $419.00 million, making it the largest holding in the fund's portfolio [2][3][4] Company Overview - HeartFlow, Inc. has a market capitalization of $2.38 billion and reported revenue of $157.75 million with a net income of -$113.33 million for the trailing twelve months [5] - As of November 14, 2025, HeartFlow's stock price was $27.98 [5] Investment Details - The new position in HeartFlow represents 27.81% of Bain Capital Life Sciences Investors, LLC's reportable assets under management [4][7] - This acquisition accounts for approximately 17% of HeartFlow's overall market capitalization, indicating a substantial investment relative to the company's size [12] Company Operations - HeartFlow specializes in non-invasive diagnostics for coronary artery disease, utilizing AI and computational fluid dynamics to create personalized 3D heart models [9][10] - The company primarily generates revenue from healthcare providers and institutions that utilize its proprietary heart modeling technology [9]